

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.unpto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/899,552	07/06/2001	Lauraine Wagter-Lesperance	6580-239	7030
7590 01/18/2007 Micheline Gravelle			EXAMINER	
Bereskin & Parr			SZPERKA, MICHAEL EDWARD	
40 King Street West Box 401			ART UNIT	PAPER NUMBER
Toronto, ON M5H 3Y2			1644	
CANADA				
			MAIL DATE	DELIVERY MODE
			01/18/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
09/899,552	WAGTER-LESPERANCE ET AL.		
Examiner	Art Unit		
Michael Szperka	1644		

The MAILING DATE of this communication appears on the cover sheet with the correspondence address
THE REPLY FILED 21 December 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3 a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:
a) The period for reply expires 3 months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, which are in lates.
no event, nowever, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST BEPLY WAS FILED WITHIN
TWO MONTHS OF THE FINAL REJECTION. See MPEP 706 07/f)
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action, or (2) a set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). AMENDMENTS
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
(a) ☑ They raise new issues that would require further consideration and/or search (see NOTE below):
(b) They raise the issue of new matter (see NOTE below);
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) They present additional claims without canceling a corresponding number of finally rejected claims.
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.116 and 41.33(a)).
4. 🛄 The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324)
5. Applicant's reply has overcome the following rejection(s):
 Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
7. For purposes of appeal, the proposed amendment(s): a) Will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows:
Claim(s) allowed: 21.
Claim(s) objected to:
Claim(s) rejected: <u>3,5-20 and 22-24</u> .
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE
3. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will <u>not</u> be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
D. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41 33(d)(1)
10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached
REQUEST FOR RECONSIDERATION/OTHER
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:
 I2. ☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s) I3. ☐ Other:

Continuation of 3. NOTE: Applicant's proposed amendments combine limitations not previously considered together. Specifically, many claims have now been added that depend from independent claim 21. During prosecution, methods of calculating immune response using a mathematical index (claim 21) were not considered in combination with limitations such as specific stress conditions (claim 56 for example), specific antigens (claim 61 for example), specific adjuvants (claim 63 for example), and differing times for immunization and antibody response measuring (claims 67-70 for example). The newly presented combinations of limitations have not been previously considered, and as such a new search and additional consideration would be required.

G.R. EWOLDT, PH.D. PRIMARY EXAMINER